Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
about
Buprenorphine for treating cancer painBuprenorphine for treating cancer painBuprenorphine - an attractive opioid with underutilized potential in treatment of chronic painMarketed New Drug Delivery Systems for Opioid Agonists/Antagonists Administration: A Rapid OverviewTransdermal buprenorphine - a critical appraisal of its role in pain management.Recent advances in the use of opioids for cancer painPharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica).Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.Transdermal buprenorphine in the management of persistent pain - safety aspects.Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal BuprenorphineOpioids switching with transdermal systems in chronic cancer pain.Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids.End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?Buprenorphine for cancer pain: is it ready for prime time?Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review.Enhancing Risk Assessment in Patients Receiving Chronic Opioid Analgesic Therapy Using Natural Language Processing.A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine.Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.Differential patterns of opioid use: defining persistent opioid use in a prescription database.Perioperative considerations for "new" kids on the opioid block.Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses.Differences between Transdermal Fentanyl and Buprenorphine in the Elderly Hospice PatientsA Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin
P2860
Q24187076-492EF39C-458C-48EE-A52C-5E89B2EE605AQ24202194-C895B524-6C62-432C-9DD1-F3D9A0D287AEQ26775658-A102BA4F-3FAD-45F7-9EBE-3953DCDAD078Q28079382-7CA630F2-D5A6-4FE5-8D8B-4294B4159D28Q34418193-2A132D26-DF65-474E-BC62-9A36F761A45FQ34418203-EE7EE101-C959-4C6E-BA8A-2F1C852F9AD6Q34620060-41689866-BF81-40D9-84B2-7EE2287D6EA1Q34787766-03824F66-89DB-4A93-811A-F5694D29ADB2Q35166793-48DB875F-B0D5-414D-ACE5-716ACBC65A76Q37173960-26240B04-F9D1-4E42-9DAC-87732F0BDF90Q37198162-13DE0993-B533-4449-81FB-7AB0A87230F3Q37613711-ABEBC37F-0575-44B0-A2AA-86140C387868Q38174282-08141F2B-0B42-4D1A-AB8E-170916BE6BCCQ38243938-499F57ED-BF3C-4FC6-B988-7F5D98247FE2Q38244523-AF73DBDD-BF70-4ABE-84A4-F8C782C0A7C8Q38399076-10C3A6AB-7231-45EA-B336-CA7ECBC5ADA6Q39051847-E1F60DA8-5058-4303-B7EE-B3EE90EDF174Q39234435-FC668339-43D5-44BE-9D99-4E12AA7F71D4Q39334344-AC7C1061-7801-4314-BF07-35CFB2972508Q39356288-18A2F669-E87C-4F57-BEAF-0E4F85716E35Q40883582-EF51F243-CFF9-4924-A38B-072111A16B81Q41466780-146B83BD-F614-448C-9CA8-C669C6D3D319Q44332914-9EA107BE-F894-49A4-8EDC-0DEE36DE4FDAQ44349612-48E3FD7C-0878-46E6-9082-3B6632084544Q44349736-251A584F-A93F-414A-8C2C-907FA58B1CD8Q58565617-114FCB15-A780-4A14-BC5E-9502208D37B8Q58593414-90ED14CF-82EF-483B-A7B1-970D5897EB1C
P2860
Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Equipotent doses of transderma ...... a retrospective cohort study.
@ast
Equipotent doses of transderma ...... a retrospective cohort study.
@en
Equipotent doses of transderma ...... a retrospective cohort study.
@nl
type
label
Equipotent doses of transderma ...... a retrospective cohort study.
@ast
Equipotent doses of transderma ...... a retrospective cohort study.
@en
Equipotent doses of transderma ...... a retrospective cohort study.
@nl
prefLabel
Equipotent doses of transderma ...... a retrospective cohort study.
@ast
Equipotent doses of transderma ...... a retrospective cohort study.
@en
Equipotent doses of transderma ...... a retrospective cohort study.
@nl
P2093
P1476
Equipotent doses of transderma ...... a retrospective cohort study.
@en
P2093
Barbara Poulsen Nautrup
Reinhard Sittl
Rudolf Likar
P304
P356
10.1016/J.CLINTHERA.2005.02.012
P577
2005-02-01T00:00:00Z